Unresectable Hepatocellular Carcinoma Hcc clinical trials

Explore recruiting unresectable hepatocellular carcinoma hcc clinical trials.

Recruiting unresectable hepatocellular carcinoma hcc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Unresectable Hepatocellular Carcinoma Hcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS SORAFENIB OR LENVATINIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB

Finland, Spain, Belgium, France, Austria, Greece +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fecal Microbiota Transplantation to RESCUE patients with unresectable Hcc progressors to first line therapy with AtezolizUmaB and Bevacizumab (RESCUE-HUB)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II Combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)

Poland, Spain, Germany, France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

INTERVENTIONAL PLATFORM STUDY INVESTIGATING THE IMPACT OF DIGITAL HEALTH SOLUTIONS ON HEALTH OUTCOMES AND HEALTH-CARE RESOURCE UTILIZATION IN PARTICIPANTS RECEIVING SYSTEMIC TREATMENT IN CLINICAL PRACTICE (ORIGAMA)

Austria, Spain, Germany

Phase II and Phase III (Integrated) EU CTIS Study details

Unresectable Hepatocellular Carcinoma Hcc trials by city

Unresectable Hepatocellular Carcinoma Hcc in Toronto Unresectable Hepatocellular Carcinoma Hcc in Vancouver Unresectable Hepatocellular Carcinoma Hcc in Montreal Unresectable Hepatocellular Carcinoma Hcc in Calgary Unresectable Hepatocellular Carcinoma Hcc in Edmonton Unresectable Hepatocellular Carcinoma Hcc in Ottawa Unresectable Hepatocellular Carcinoma Hcc in Winnipeg Unresectable Hepatocellular Carcinoma Hcc in Quebec City Unresectable Hepatocellular Carcinoma Hcc in Hamilton Unresectable Hepatocellular Carcinoma Hcc in Kitchener Unresectable Hepatocellular Carcinoma Hcc in London Unresectable Hepatocellular Carcinoma Hcc in Halifax Unresectable Hepatocellular Carcinoma Hcc in New York Unresectable Hepatocellular Carcinoma Hcc in Los Angeles Unresectable Hepatocellular Carcinoma Hcc in Chicago Unresectable Hepatocellular Carcinoma Hcc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease